According to the findings, an added benefit is not proven: For patients with moderate COPD severity and patients with fewer than two acute flare-ups (exacerbations) per year, evaluable data were only ...

HealthDay News — A combination of fluticasone furoate and vilanterol reduces the rate of moderate or severe exacerbations among patients with chronic obstructive pulmonary disease (COPD), according to ...

Study authors performed a post hoc pooled analysis of data from 10 trials to assess the safety and efficacy of umeclidinium/vilanterol in elderly symptomatic patients with COPD.

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

The US Food and Drug Administration (FDA) today approved umeclidinium and vilanterol powder for inhalation (Anoro Ellipta, GlaxoSmithKline (GSK)/Theravance). The drug is the first combo bronchodilator ...

Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA? Treatment with once-daily single-inhaler fluticasone ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

Fluticasone furoate/vilanterol (FF/VI) improved FEV1 but did not improve morning peak expiratory flow in pediatric patients with uncontrolled asthma. Among pediatric patients with uncontrolled asthma, ...

Utility of circulating tumor DNA in patients with resectable pancreatic cancer using a patient-specific panel: ARTEMIS-PC study. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal ...